-
Goldman Sachs Reiterates Neutral Rating on Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY)
-
Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) PT Raised to INR1,100 at Jefferies
-
Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) PT Raised to INR1,200 at Goldman Sachs
-
Dr. Reddys Labs (RDY) Misses Q2 EPS by 1c
-
Morgan Stanley Starts Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY) at Equalweight
-
Macquarie Downgrades Dr. Reddy's Laboratories (DRRD:IN) (RDY) to Neutral
-
Dr. Reddy's (RDY) stock rises on biosimilar collaboration with Alvotech (ALVO)
-
HSBC Upgrades Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) to Buy
-
Dr. Reddys Labs (RDY) Tops Q1 EPS by 1c
-
Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,060 at JPMorgan
-
Bio-Thera and Dr. Reddy's (RDY) Execute Exclusive Commercialization Agreement for BAT2206
-
Buy this stock as Trump's 'tariff chaos' is priced-in: BofA
-
CLSA Downgrades Dr. Reddy's Laboratories (DRRD:IN) (RDY) to Underperform (4)
-
Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) PT Raised to INR1,620 at BofA Securities
-
Nuvama Upgrades Dr. Reddy\'s Laboratories (DRRD:LN) (RDY) to Buy
-
Nomura/Instinet Upgrades Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) to Buy
-
Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) PT Raised to INR1,110 at Citi
-
BofA Securities Reiterates Buy Rating on Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY)
-
UBS Starts Dr. Reddy's Laboratories (DRRD:IN) (RDY) at Sell
-
Dr. Reddys Labs (RDY), Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
-
Dr. Reddys Labs (RDY) Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
-
Dr. Reddys Labs (RDY) Tops Q2 EPS by 5c
-
Investec Reiterates Buy Rating on Dr. Reddy\'s Laboratories (DRRD:LN) (RDY)
-
Citi Reiterates Sell Rating on Dr. Reddy\'s Laboratories (DRRD:IN) (RDY)
-
Dr. Reddys Labs (RDY) to Acquire Nicotinell and Related Portfolio

